Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227564 · ClinicalTrials.gov registry record · Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01227564: Completed Phase 2 study, sponsored by Pfizer.
NCT01227564 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01227564, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
Primary Outcome
Fibrillar brain Aβ was measured by retention of florbetapir F18 as measured by positron emission tomography (PET) scans. A positive change indicating an improvement from baseline.
Interventions
- BIOLOGICAL ACC-001 3 μg/ QS-21 50 μg
- BIOLOGICAL ACC-001 10 μg/ QS-21 50 μg
- OTHER Placebo- Phosphate buffered saline (PBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01227564 record still lists
NCT01227564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which ACC-001 3 μg/ QS-21 50 μg is the first listed.
NCT01227564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01227564 about?
NCT01227564 is a clinical study titled "Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease". This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
What is the current status of trial NCT01227564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2011-02. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01227564?
The interventions under investigation include: ACC-001 3 μg/ QS-21 50 μg (BIOLOGICAL), ACC-001 10 μg/ QS-21 50 μg (BIOLOGICAL), Placebo- Phosphate buffered saline (PBS) (OTHER).
Who is sponsoring clinical trial NCT01227564?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01227564's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia